‘A New Lease on Life’: Breakthrough Cancer Drug Brings Hope to Hundreds of Australians with Rare Condition
- A rare genetic disorder, Von Hippel Lindau disease, is gaining attention with a new life-changing treatment
- Patients and families are rejoicing at the prospect of a normal life, but advocates warn more research is needed
- A breakthrough drug, Belzutifan, has been listed on the Pharmaceutical Benefits Scheme, making it affordable for those in need
- But experts say more funding is required to tackle the complexities of neuroendocrine cancers
Lana Hallowes, 25, has spent most of her life in and out of hospital, her body ravaged by the relentless onslaught of tumours caused by Von Hippel Lindau disease (VHL).
Diagnosed at just 11 years old, Lana has endured countless surgeries, including four brain surgeries and spinal cord surgery, and has had to relearn how to walk five times.
Her life has been a never-ending cycle of scans, surgeries, and hospital visits. But all that has changed with the arrival of a breakthrough drug, Belzutifan.
For the first time in her life, Lana doesn’t need surgery, and she’s planning holidays with her boys.
The drug, which was listed on the Pharmaceutical Benefits Scheme (PBS) earlier this year, has been a game-changer for Lana and hundreds of others living with VHL.
Before its listing, treatment cost up to $12,000 a month, a staggering sum that was out of reach for many. Now, it’s just $25.
VHL is a rare hereditary condition that causes recurring tumours all over the body. There is no cure, and patients like Lana have to live with the constant threat of new tumours forming.
But Belzutifan has brought new hope to those affected. The drug works by inhibiting the growth of tumours, giving patients a much-needed reprieve from the cycle of surgery and hospital visits.
According to Health Minister Mark Butler, the listing of Belzutifan on the PBS is a testament to the scheme’s ability to bring life-changing medicines to Australians at affordable prices.
“It’s just a demonstration of the magic of the PBS bringing the world’s best medicines to Australia at affordable prices,” he said.
But despite the breakthrough, advocates warn that more research is needed to find a cure for VHL. Neuroendocrine cancers, like VHL, remain widely misunderstood, and treatment options are limited.
Advocates are calling for greater funding for more targeted therapies to tackle the complexities of these cancers.
Analysis: What This Means for Australia
The listing of Belzutifan on the PBS is a significant step forward for patients with VHL, but it also highlights the need for greater investment in medical research.
Australia has a strong reputation for innovative healthcare, but more needs to be done to support patients with rare and complex conditions. The government must prioritize funding for research into neuroendocrine cancers, like VHL, to ensure that patients have access to the best possible treatments.
Security analysts say that the development of new treatments for rare cancers is a matter of national priority.
“The fact that Belzutifan has been listed on the PBS is a positive step, but we need to see more investment in research and development to ensure that patients have access to the latest treatments,” said one analyst.
Law enforcement insiders also warn that the high cost of treatments for rare conditions can lead to a black market for medications, putting patients at risk.
“We need to ensure that patients have access to affordable treatments, and that we’re not creating a situation where people are forced to turn to the black market,” said a law enforcement official.
